Suppr超能文献

青霉胺诱导的蛋白尿与既往金制剂肾病之间的关系。

The relationship between D-penicillamine--induced proteinuria and prior gold nephropathy.

作者信息

Billingsley L M, Stevens M B

出版信息

Johns Hopkins Med J. 1981 Feb;148(2):64-7.

PMID:7206401
Abstract

Twenty-five patients with rheumatoid arthritis treated with D-penicillamine were retrospectively reviewed for signs of drug intolerance. Nine patients (36%) developed adverse drug reactions, the most common of which was proteinuria in six patients (24%). Comparative analysis of patients with and without penicillamine-induced proteinuria revealed the only significant correlate to be a previous history of gold nephropathy. Five (83%) of six patients who developed penicillamine-induced proteinuria had had gold-induced proteinuria; in contrast, only three (20%) of 19 who tolerated penicillamine had prior gold-induced proteinuria (p less than .01). HLA typing performed in five of the six patients with penicillamine nephropathy revealed DRw4 at a prevalence less than that expected for a population with rheumatoid arthritis, with DRw3 and/or B8 present in four patients. Further studies are in progress to determine whether a genetic predisposition is present. These data suggest that cautious observation is warranted in rheumatoid patients receiving D-penicillamine who have a prior history of gold nephropathy.

摘要

对25例接受青霉胺治疗的类风湿性关节炎患者进行回顾性研究,以观察药物不耐受迹象。9例患者(36%)出现药物不良反应,其中最常见的是6例患者(24%)出现蛋白尿。对有和无青霉胺诱导蛋白尿患者的比较分析显示,唯一显著相关因素是既往有金制剂肾病病史。6例出现青霉胺诱导蛋白尿的患者中有5例(83%)有金制剂诱导的蛋白尿;相比之下,19例耐受青霉胺的患者中只有3例(20%)有既往金制剂诱导的蛋白尿(p小于0.01)。对6例青霉胺肾病患者中的5例进行HLA分型,结果显示DRw4的发生率低于类风湿性关节炎患者群体的预期,4例患者同时存在DRw3和/或B8。正在进行进一步研究以确定是否存在遗传易感性。这些数据表明,对于有金制剂肾病病史且接受青霉胺治疗的类风湿性关节炎患者,有必要进行谨慎观察。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验